Skip to main content

Free Content Pyridoxal 5′-phosphate deficiency causes a loss of aromatic l-amino acid decarboxylase in patients and human neuroblastoma cells, implications for aromatic l-amino acid decarboxylase and vitamin B6 deficiency states

Download Article:

You have access to the full text article on a website external to Ingenta Connect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

J. Neurochem. (2010) 114, 87–96. Abstract

Pyridoxal 5′-phosphate, the active form of vitamin B6, is an essential cofactor for multiple enzymes, including aromaticl-amino acid decarboxylase that catalyses the final stage in the production of the neurotransmitters dopamine and serotonin. In two patients with inherited disorders of vitamin B6 metabolism, we observed reductions in plasma aromaticl-amino acid decarboxylase activity. In one patient, this change was related to an increase in Km for pyridoxal 5′-phosphate. Furthermore, pyridoxal 5′-phosphate-deficient human SH-SY5Y neuroblastoma cells were found to exhibit reduced levels of aromaticl-amino acid decarboxylase activity and protein but with no alteration in expression. Further reductions in activity and protein were observed with the addition of the vitamin B6 antagonist 4-deoxypyridoxine, which also reduced aromaticl-amino acid decarboxylase mRNA levels. Neither pyridoxal 5′-phosphate deficiency nor the addition of 4-deoxypyridoxine affected aromaticl-amino acid decarboxylase stability over 8 h with protein synthesis inhibited. Increasing extracellular availability of pyridoxal 5′-phosphate was not found to have any significant effect on intracellular pyridoxal 5′-phosphate concentrations or on aromaticl-amino acid decarboxylase. These findings suggest that maintaining adequate pyridoxal 5′-phosphate availability may be important for optimal treatment of aromaticl-amino acid decarboxylase deficiency andl-dopa-responsive conditions.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: AADC deficiency; PNPO deficiency; Parkinson’s disease; dopamine; serotonin; vitamin B6

Document Type: Research Article

Affiliations: 1: Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK 2: Neurometabolic Unit, National Hospital for Neurology and Neurosurgery, London, UK 3: Clinical and Molecular Genetics Unit, UCL Institute of Child Health, London, UK 4: Medical Neurogenetics, Atlanta, Georgia, USA

Publication date: 01 July 2010

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more